News

Subject to shareholder approval, the combined company will retain the name Rocket Pharmaceuticals and will be headquartered in New York City.  The combined company will focus on developing

The FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) had unanimously voted that the data tabled by GSK supported the efficacy and safety of its shingles candidate

The top-line data from the trial has demonstrated that the novel topical wound-healing agent SD-101 did not meet the primary endpoints or secondary endpoints in patient with epidermolysis

Livatag could not improve survival of the HCC patients when compared to best standard of care according to the findings of the phase 3 trial dubbed as ReLive.

Results show that Imfinzi (durvalumab) demonstrated a statistically-significant and clinically-meaningful improvement in PFS compared to current standard of care with active surveillance in patients with locally-advanced (Stage III),

The funds will support the clinical and regulatory development of ridinilazole for the treatment of CDI, including Summit’s planned Phase 3 development program. Ridinilazole is a highly selective,

“The results presented today demonstrate that IRX-2, a primary cell-derived biologic, drives intratumoral immune infiltration of T cells, B cells and dendritic cells, promoting their activation. “This increase

According to the agreement, HitGen will apply its advanced technology platform, based on DNA-encoded library design, synthesis and screening, to discover novel leads which will be licensed exclusively

The Johnson & Johnson company said that by stopping development of JNJ-4178, its investigational hepatitis C treatment regimen, it would focus on addressing significant unmet needs in chronic